Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 290.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 4.00 (1.384%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Price Monitoring Extn

10 Jun 2019 12:07

RNS Number : 6989B
Hutchison China Meditech Limited
10 June 2019
 

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
APMGGUMUQUPBGGU
Date   Source Headline
21st Apr 20229:30 amRNSVesting of awards under Long Term Incentive Plan
31st Mar 20227:00 amRNSUpdate on Status under HFCAA
23rd Mar 20228:30 amRNS2021 Annual Report and Notice of AGM
11th Mar 20229:00 amRNSUpdate on Status under HFCAA
9th Mar 20228:30 amRNSVesting of awards under Long Term Incentive Plan
7th Mar 20227:00 amRNSHUTCHMED Receives $15m Milestone from AstraZeneca
3rd Mar 20223:30 pmRNSPublication of Form 20-F
3rd Mar 202212:30 pmRNSRetirement of CEO and appointment of new CEO
3rd Mar 202212:00 pmRNSFull Year Results and Business Updates
1st Mar 20228:30 amRNSApproval to Commercialize ELUNATE® in Macau
7th Feb 20228:30 amRNSHUTCHMED to Announce 2021 Final Results
4th Feb 20229:30 amRNSPhase Ib/II Combination Study of HMPL-453
20th Jan 20227:00 amRNSHUTCHMED Initiates Phase I Trial of HMPL-653
19th Jan 20227:00 amRNSHUTCHMED Data at ASCO GI Cancers Symposium
17th Jan 20229:00 amRNSHolding(s) in Company
12th Jan 202211:00 amRNSBreakthrough Therapy Designation for HMPL-523
10th Jan 20227:00 amRNSHUTCHMED Initiates Phase I Study of HMPL-760
31st Dec 20217:00 amRNSBlocklisting Six Monthly Return
31st Dec 20217:00 amRNSTotal Voting Rights
20th Dec 20217:00 amRNSHUTCHMED Included in FTSE Russell Indexes
15th Dec 20219:45 amRNSGrant of Share Options and Awards under LTIP
14th Dec 20217:00 amRNSHMPL-523 Clinical Data Presented at ASH
10th Dec 202110:00 amRNSHUTCHMED Presents Data at ESMO Immuno-Oncology ‘21
6th Dec 20217:00 amRNSHUTCHMED Completes Planned Enrollment of FRESCO-2
3rd Dec 20217:00 amRNSUpdated NRDL to include ELUNATE and SULANDA
30th Nov 20218:30 amRNSTotal Voting Rights
24th Nov 20217:00 amRNSHUTCHMED and AZ Initiate SACHI Phase 3 Trial
8th Nov 20217:00 amRNSHUTCHMED to Present Clinical Data at ASH
1st Nov 20217:00 amRNSHUTCHMED and AZ Initiate SAMETA Global P3 Trial
29th Oct 20219:30 amRNSTotal Voting Rights
28th Oct 20217:00 amRNSHUTCHMED Initiates Phase III Trial of HMPL-523
20th Oct 20219:30 amRNSGrant of Awards under Long Term Incentive Plan
30th Sep 20219:30 amRNSTotal Voting Rights
29th Sep 20217:00 amRNSClosure of Non-Core OTC Joint Venture Divestment
29th Sep 20217:00 amRNSHUTCHMED Highlights Presentations at CSCO 2021
21st Sep 20217:00 amRNSHUTCHMED Initiates Phase III Trial SURTORI-01
20th Sep 20217:00 amRNSJapan Bridging Study For Surufatinib Initiated
13th Sep 20217:00 amRNSBreakthrough Therapy Designation for Amdizalisib
8th Sep 202111:30 amRNSHUTCHMED and AZ Initiate Phase III Trial in China
7th Sep 20219:30 amRNSHUTCHMED to Present Clinical Data at ESMO
2nd Sep 202112:45 pmRNSGrant of Share Options, and Awards under LTIP
31st Aug 20219:30 amRNSTotal Voting Rights
26th Aug 20217:00 amRNSPhase Ib/II Trial of Fruquintinib & Tislelizumab
23rd Aug 20217:00 amRNSHUTCHMED Selected for Certain Hang Seng Indexes
17th Aug 20219:30 amRNSELECTRONIC COMMUNICATION OF CORPORATE INFORMATION
9th Aug 20217:00 amRNSHUTCHMED & Epizyme Announce TAZVERIK Collaboration
30th Jul 20219:30 amRNSTotal Voting Rights
28th Jul 202112:00 pmRNSInterim Results and Business Updates
28th Jul 20217:00 amRNSPhase II Trial of ORPATHYS Initiated
23rd Jul 202112:01 pmRNSStabilizing Actions & End of Stabilization Period

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.